Department of Palliative and Supportive Care, Okayama University Hospital, Okayama city, Japan.
Clinical Cancer Center, Okayama University Hospital, Okayama city, Japan.
J Palliat Care. 2024 Jul;39(3):238-243. doi: 10.1177/08258597231221924. Epub 2023 Dec 19.
Corticosteroids are commonly used for symptom relief in patients with terminal cancer, but their use may have an impact on patient survival. We compared the survival of patients with terminal cancer who did and did not receive corticosteroid treatment for symptom relief, stratified by their predicted prognosis. We retrospectively reviewed consecutive patients with cancer who received corticosteroid treatment for symptom relief in a single palliative care unit. We stratified the patients according to their predicted prognosis using the palliative prognostic (PaP) score either before starting the corticosteroid treatment or at admission for control patients who did not receive a corticosteroid treatment. The 2 groups were compared for survival based on the PaP Scores. We analyzed 204 patients treated with a corticosteroid during the study period and 139 control patients who did not receive corticosteroids during their treatment. No difference was observed in the survival between the treatment and control groups. Corticosteroid treatment for symptom relief in patients with terminal cancer did not affect survival time.
皮质类固醇常用于缓解终末期癌症患者的症状，但它们的使用可能会影响患者的生存。我们比较了接受皮质类固醇治疗以缓解症状的终末期癌症患者和未接受皮质类固醇治疗的患者的生存情况，这些患者的预后是分层的。我们回顾性地审查了在一个姑息治疗病房接受皮质类固醇治疗以缓解症状的连续癌症患者。我们使用姑息预后（PaP）评分根据患者的预计预后对患者进行分层，该评分在开始皮质类固醇治疗之前或在未接受皮质类固醇治疗的对照患者入院时进行。根据 PaP 评分比较两组患者的生存情况。我们分析了研究期间接受皮质类固醇治疗的 204 名患者和未接受皮质类固醇治疗的 139 名对照患者。治疗组和对照组之间的生存时间没有差异。皮质类固醇治疗终末期癌症患者的症状缓解并未影响生存时间。
